328 related articles for article (PubMed ID: 27162119)
21. Vitamin D receptor expression in canine mammary gland and relationship with clinicopathological parameters and progesterone/oestrogen receptors.
Sánchez-Céspedes R; Fernández-Martínez MD; Raya A; Pineda C; López I; Millán Y
Vet Comp Oncol; 2018 Mar; 16(1):E185-E193. PubMed ID: 29178579
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical evaluation of Ki-67, PCNA and MCM2 proteins proliferation index (PI) in advanced gastric cancer.
Czyzewska J; Guzińska-Ustymowicz K; Pryczynicz A; Kemona A; Bandurski R
Folia Histochem Cytobiol; 2009; 47(2):289-96. PubMed ID: 19995716
[TBL] [Abstract][Full Text] [Related]
23. Expression of iNOS, COX-2 and VEGF in canine mammary tumours and non-neoplastic mammary glands: Association with clinicopathological features and tumour grade.
Anadol E; Yar Saglam AS; Gultiken N; Karakas K; Alcigir E; Alkan H; Kanca H
Acta Vet Hung; 2017 Sep; 65(3):382-393. PubMed ID: 28956485
[TBL] [Abstract][Full Text] [Related]
24. MIB-1 labelling indices according to clinico-pathological variables in canine mammary tumours: a multivariate study.
De Matos AJ; Lopes CC; Faustino AM; Carvalheira JG; Dos Santos MS; Rutteman GR; Gärtner Mde F
Anticancer Res; 2006; 26(3A):1821-6. PubMed ID: 16827113
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases.
Hellmén E; Bergström R; Holmberg L; Spångberg IB; Hansson K; Lindgren A
Vet Pathol; 1993 Jan; 30(1):20-7. PubMed ID: 8442324
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical identification method of tumour cells in the S phase of mitotic cycle and its usefulness in diagnostics of mammary gland adenocarcinomas in bitches.
Nowak M; Madej JA; Dziegiel P; Kanzawa H
Pol J Vet Sci; 2006; 9(1):57-62. PubMed ID: 16573276
[TBL] [Abstract][Full Text] [Related]
27. Clinical and pathological prognostic factors in canine mammary tumors.
Pérez Alenza MD; Peña L; Nieto AI; Castaño M
Ann Ist Super Sanita; 1997; 33(4):581-5. PubMed ID: 9616968
[TBL] [Abstract][Full Text] [Related]
28. Proliferation indices in spontaneous canine lung cancer: proliferating cell nuclear antigen (PCNA), Ki-67 (MIB1) and mitotic counts.
Griffey SM; Kraegel SA; Madewell BR
J Comp Pathol; 1999 May; 120(4):321-32. PubMed ID: 10208729
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary tumours: a survival study.
Santos A; Lopes C; Frias C; Amorim I; Vicente C; Gärtner F; Matos Ad
Vet J; 2011 Dec; 190(3):396-402. PubMed ID: 21269852
[TBL] [Abstract][Full Text] [Related]
30. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
Gama A; Alves A; Schmitt F
Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
[TBL] [Abstract][Full Text] [Related]
31. Expression of connexins 26 and 43 in canine hyperplastic and neoplastic mammary glands.
Torres LN; Matera JM; Vasconcellos CH; Avanzo JL; Hernandez-Blazquez FJ; Dagli ML
Vet Pathol; 2005 Sep; 42(5):633-41. PubMed ID: 16145209
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of histological grading in noninflammatory canine mammary carcinomas in a prospective study with two-year follow-up: relationship with clinical and histological characteristics.
Peña L; De Andrés PJ; Clemente M; Cuesta P; Pérez-Alenza MD
Vet Pathol; 2013 Jan; 50(1):94-105. PubMed ID: 22688585
[TBL] [Abstract][Full Text] [Related]
33. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors.
Lee CH; Kim WH; Lim JH; Kang MS; Kim DY; Kweon OK
J Vet Sci; 2004 Mar; 5(1):63-9. PubMed ID: 15028887
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors.
Chang CC; Tsai MH; Liao JW; Chan JP; Wong ML; Chang SC
J Am Vet Med Assoc; 2009 Aug; 235(4):391-6. PubMed ID: 19681719
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral FoxP3 expression is associated with angiogenesis and prognosis in malignant canine mammary tumors.
Carvalho MI; Pires I; Prada J; Gregório H; Lobo L; Queiroga FL
Vet Immunol Immunopathol; 2016 Oct; 178():1-9. PubMed ID: 27496736
[TBL] [Abstract][Full Text] [Related]
36. Loss of p27 expression in canine mammary tumors and their metastases.
Klopfleisch R; Schütze M; Gruber AD
Res Vet Sci; 2010 Apr; 88(2):300-3. PubMed ID: 19748645
[TBL] [Abstract][Full Text] [Related]
37. Assessing the Interleukin 35 Immunoexpression in Malignant Canine Mammary Tumors: Association With Clinicopathological Parameters and Prognosis.
Carvalho MI; Pires I; Prada J; Pinto C; Gregório H; Cogliati B; Queiroga FL
Anticancer Res; 2019 Apr; 39(4):2077-2083. PubMed ID: 30952752
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002).
Chang SC; Chang CC; Chang TJ; Wong ML
J Am Vet Med Assoc; 2005 Nov; 227(10):1625-9. PubMed ID: 16313041
[TBL] [Abstract][Full Text] [Related]
39. Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance.
Nieto A; Peña L; Pérez-Alenza MD; Sánchez MA; Flores JM; Castaño M
Vet Pathol; 2000 May; 37(3):239-47. PubMed ID: 10810988
[TBL] [Abstract][Full Text] [Related]
40. Nuclear pleomorphism: role in grading and prognosis of canine mammary carcinomas.
Santos M; Correia-Gomes C; Santos A; de Matos A; Rocha E; Lopes C; Pereira PD
Vet J; 2014 Jun; 200(3):426-33. PubMed ID: 24745769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
